Outstanding 2021 for Paragon Biosciences and Our Portfolio Companies
Chicago, Dec. 16, 2021 – Paragon Biosciences has had a stellar year of achievements in 2021, advancing our mission to solve some of society’s most [...]
PARAGON BIOSCIENCES EARNS 2021 GREAT PLACE TO WORK™ CERTIFICATION
Chicago, Dec. 7, 2021 – Paragon Biosciences is proud to announce that it has been certified as a Great Place to Work®. This prestigious [...]
Paragon’s Portfolio Company Emalex Biosciences Announces Positive Topline Results from Phase 2b Clinical Study Evaluating Ecopipam for Pediatric Tourette Syndrome
Statistically significant, clinically meaningful results obtained on the primary and multiple secondary efficacy endpoints; ecopipam well tolerated in the study Chicago, Nov. 10, 2021 – [...]
Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disorder
Current enrollment for stuttering study is at 75%; Nine U.S. Sites Nationwide Chicago, September 14, 2021 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused [...]
Emalex Biosciences Announces Completion of Patient Enrollment in Phase 2b Clinical Trial Evaluating Ecopipam (EBS-101) for Pediatric Patients with Tourette Syndrome
Paragon Biosciences’ Portfolio Company Focuses on Areas with High Unmet Needs Chicago, June 22, 2021 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused [...]
Sai Chavala, M.D., Receives ARVO Foundation Ludwig Von Sallmann Clinician-Scientist Award
Dr. Chavala is co-founder of CiRC Biosciences with Jeff Aronin, chairman and CEO of Paragon Biosciences Chicago, June 3, 2021—CiRC Biosciences, Inc., Co-Founder and [...]
